
The US Biomedical Advanced Research and Development Authority (BARDA), which falls under the US Department of Health and Human Services, has exercised an option in a contract with Danish vaccine firm Bavarian Nordic, the firm has announced in a Wednesday press release.
The option is valued at USD 119m, and means that Bavarian can start manufacturing its first doses of its freeze-dried version of Jynneos, a smallpox vaccine, in 2023 and 2024.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app